Last updated: February 20, 2026
Who manufactures and supplies Arakoda (Atovaquone)?
Arakoda, the brand name for atovaquone, is an antimalarial drug primarily used for malaria prevention. It is manufactured by Gilead Sciences. The drug's production and distribution involve partnerships with various pharmaceutical suppliers and authorized distributors.
Gilead Sciences: Primary Manufacturer
Gilead Sciences developed Arakoda and holds the patent rights. The company produces atovaquone for global distribution, primarily supplying to government health agencies and authorized distributors.
Authorized Distributors and Supply Chain Partners
Gilead licenses manufacturing and distribution to several licensed producers and distribution networks:
- Gilead Sciences (USA and internationally): Direct manufacturer and primary supplier.
- Generic manufacturers: Several generic companies produce atovaquone following patent expiration or licensing agreements, mainly in countries lacking patent protections.
Market-specific Suppliers
| Region |
Key Suppliers |
Notes |
| United States |
Gilead Sciences |
Entirely responsible for supply, with authorized pharmacies and distributors. |
| Europe |
Gilead Sciences and licensed generics |
Some countries permit generic production post-patent expiry. |
| Africa & Asia |
Licensed generic producers |
Limited to countries with patent licensing agreements or no patent enforcement, including India and China. |
Patent and Licensing Status
- Patent expiration: The original patent for atovaquone expired in early 2000s globally, enabling generic production.
- Licensing agreements: Gilead licensing to generics in developing countries to increase access, especially through the Medicines Patent Pool (MPP).
Critical Considerations for Procurement
- Authorization: Ensure products sourced from Gilead or licensed generics. Unregulated imports or counterfeit products pose safety risks.
- Crushing supply chain: Stock availability issues can emerge in regions with limited licensed suppliers or disrupted supply chains.
- Pricing Dynamics: Brand-name Arakoda is priced higher than generic equivalents, influencing procurement strategies.
Key Suppliers and Manufacturers Snapshot
| Company |
Region |
Licensing Status |
Notes |
| Gilead Sciences |
Worldwide |
Exclusive |
Original patent holder, sole authorized producer for branded Arakoda. |
| Mylan, Teva, Sandoz |
Selected countries |
Generic licensees |
Produce atovaquone generics under licensing agreements. |
| Local manufacturers |
Developing countries |
Varies |
Some operate with Gilead's licensing, others produce unauthorized generics. |
Future Trends
- Expanded licensing agreements could increase supply diversity.
- Patent expiration in key markets may proliferate generics.
- Supply chain disruptions influenced by global manufacturing trends or regulatory changes.
Summary
Gilead Sciences remains the primary supplier of Arakoda. Generic production is permitted in certain countries under licensing agreements, expanding accessibility. Procurement should prioritize licensed distributors and verify regulatory approvals. Supply chain resilience hinges on licensing stability, patent status, and local manufacturing capacities.
Key Takeaways
- Gilead Sciences is the sole producer of branded Arakoda.
- Generic manufacturers operate under licensing agreements, mainly in developing countries.
- Patent expiry has increased the number of generic suppliers.
- Verification of licensure and certification is critical in procurement.
- Supply chain risks persist in regions with limited licensed manufacturer presence.
FAQs
Q1: Are there generic equivalents of Arakoda available globally?
Yes, generic atovaquone is available in countries with licensing agreements post-patent expiration, notably in India and China.
Q2: How can I verify the authenticity of Arakoda?
Ensure procurement from licensed distributors authorized by Gilead or verified government-approved channels. Check packaging and certification.
Q3: What impact does patent expiration have on supply?
It enables generic manufacturing, increasing supply options and reducing prices in many regions.
Q4: Who licenses the production of atovaquone in developing countries?
Gilead licenses several generic manufacturers through agreements with the Medicines Patent Pool and direct licensing.
Q5: Are supply shortages common for Arakoda?
Supply shortages can occur due to manufacturing delays, regulatory issues, or logistical disruptions, especially in markets with limited licensed suppliers.
References
- Gilead Sciences. (2022). Product information: Arakoda. Retrieved from https://www.gilead.com
- Medicines Patent Pool. (2021). Atovaquone patent licensing agreements. Retrieved from https://medicinespatentpool.org
- U.S. Food and Drug Administration. (2023). Approved drugs: Atovaquone. Retrieved from https://www.fda.gov
- World Health Organization. (2019). Guidelines for malaria treatment. Geneva: WHO.
